Competition for Cholesterol Players

September 30, 2019

Competition for Cholesterol Players

The Medicines Company (MDCO) recently reported top-line pivotal data on its siRNA candidate inclisiran, which targets the PCSK9 (proprotein convertase subtilisin/kexin type 9) pathway for lowering cholesterol. According to MDCO, inclisiran reduces levels of LDL cholesterol with just two injections annually. As a premium courier, Yourway functions as the backbone of the supply chain, allowing new therapies to reach patients more efficiently.

Back to Index

Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

Clinical Trial Supply West Coast

September 22-23, 2026
Burlingame, CA

Schedule a Meeting

Clinical Trial Supply Forum US

October 6-7, 2026
San Francisco, CA

Schedule a Meeting

Media

Articles

When Every Shipment Represents a Patient

Open chat

Hello! How can I help you?